OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms GERCOR VELVET; VELVET
- 05 Apr 2017 Results of a biomarker analysis presented at the 108th Annual Meeting of the American Association for Cancer Research
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Dec 2016 Results of a biomarker analysis presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics